Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 237-410-6 | CAS number: 13775-53-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vivo
Administrative data
- Endpoint:
- in vivo mammalian somatic cell study: cytogenicity / bone marrow chromosome aberration
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP-compliant OECD guideline study, available two unpublished reports, no restrictions, fully adequate for assessment.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 997
- Report date:
- 1997
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 475 (Mammalian Bone Marrow Chromosome Aberration Test)
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.11 (Mutagenicity - In Vivo Mammalian Bone-Marrow Chromosome Aberration Test)
- GLP compliance:
- yes
- Type of assay:
- chromosome aberration assay
Test material
- Details on test material:
- Name of test substance: sodium hexafluoroaluminate
Manufacturer: BAYER AG
Batch number: 2
Content: 98.9%
Approved: until September 10, 1997
Appearance: powder
Storage: dry at room temperature ín the dark
Common name: Cryolite (Kryolith synth.)
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles river Limited (Manston Road Margate, UK)
- Age at study initiation: approximately 6 weeks
- Weight at study initiation: 142-146 g
- Housing: 5 or 6 of the same sex in a cage
- Diet: ad libitum, standard quality-controlled laboratory rat food
- Water: ad libitum, tap water
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21±3
- Humidity (%): 55±15
- Photoperiod (hrs dark / hrs light): 12 hours
Administration / exposure
- Route of administration:
- inhalation: aerosol
- Vehicle:
- none (unchanged)
- Details on exposure:
- This cytogenetic test was run within the 13-week inhalation study. Satellite animals (male only) were included for determination of chromosomal aberrations at the end of 13 weeks exposure. Six male rats were held but not exposed during the 13 weeks of exposures, at the end of which time they were dosed intraperitoneally with cyclophosphamide as a positive control.
- Duration of treatment / exposure:
- 13 weeks
- Frequency of treatment:
- 6 hours/day, 5 days/week
- Post exposure period:
- 24 hours
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
5.0 mg/m3
Basis:
other: target concentration
- Remarks:
- Doses / Concentrations:
4.6 mg/m3
Basis:
analytical conc.
- No. of animals per sex per dose:
- 6 males
- Control animals:
- yes
- Positive control(s):
- The animals in the positive contol group were treated with a single intraperitoneal injection of cyclophosphamide at a dosage of 25 mg/kg bw using a standard dose volume of 10 ml/kg bw. The dosing was performed so as to coincide with the time of completion of the 13 week inhalation study.
Examinations
- Tissues and cell types examined:
- bone marrow (from femurs)
- Details of tissue and slide preparation:
- Approximately 2.5 hours prior to sacrifice, all satellite animals were treated with colchicine by intraperitoneal injection at a dose level of 4 mg/kg bw to arrest dividing cells at metaphase. Colchicine was formulated on the day of use as a solution in 0.9% saline at a concentration of 0.4 mg/ml.
Six satellite male rats in the negative control and the test substance treated group were sacrificed (by cervical dislocation) 24 hours after completion of treatment. Six male rats dosed-with a single intraperitoneal injection of cyclophosphamide at 25 mg/kg bw in the positive control satellite group were sacrificed 24 hours after dosing.
Both femurs were dissected from each animal. The distal heads were kept intact and as much tissue as possible was removed from the bones. Bone marrow was aspirated with Hanks' balanced salts solution then treated with a hypotonic potassium chloride solution. The cells were fixed and a homogenous cell suspension was prepared. At least four slides were prepared from each animal. Two of these slides from each animal were stained in Giemsa. - Evaluation criteria:
- The test was considered positive if, at any of the intervals, there was a biologically relevant increase in the number of metaphases with aberrations excluding gaps and/or the number of metaphases with exchanges. A test was considered negative if there was no such relevant or significant increase.
Results and discussion
Test results
- Sex:
- male
- Genotoxicity:
- negative
- Toxicity:
- no effects
- Remarks:
- increased inorganic fluoride concentrations in urine, bones, and teeth were evident for rats in exposed to 4.6 mg/m3 cryolite in the 90 days inhalation toxicity study (see repeated dose toxicity) showing systemic exposure to cryolite
- Vehicle controls validity:
- not applicable
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- The mitotic indices showed no relevant differences between the treated group and the negative control.
There were no treatment-related variations between the negative control and exposed group with respect to the parameters relevant to assessment of a clastogenic effect (metaphases with aberrations including or excluding gaps and metaphases with exchanges) . None of the parameters were significantly increased.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.
Find out more on how we use cookies.